ClinicalTrials.gg

Program

IBI3002

A development code.

Its studies are mostly in Asthma · Dermatitis, Atopic, led by Innovent Biologics.

Furthest: phase 2, since Jan 15, 20263 company-led studies, 1 open or runningNext primary completion: Mar 23, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics31 open or runningphase 2since Jan 15, 2026Jan 10, 2024Mar 23, 2027phase 2 · NCT07399067

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 10, 2024First study: phase 1 study in AsthmaFirst studyNCT06213844 · 52 enrolled · Australia
  2. Apr 10, 2025Phase 1 study in AsthmaNCT06947408 · 44 enrolled · China
  3. Jan 15, 2026Phase 2 study in Dermatitis, AtopicPhase 2 reachedNCT07399067 · 120 planned · China

Ahead

  1. Mar 23, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07399067

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07399067Dermatitis, Atopic · China2RecruitingMar 23, 2027120
NCT06947408Asthma · China1CompletedMay 11, 202644
NCT06213844Asthma · Australia1CompletedJul 22, 202552

How it is read

Names in the registry

  • “IBI3002”, 3 entries

Codes read as this program: IBI3002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.